Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J. Overman, Thierry André, Heinz‐Josef Lenz et al.|The Lancet Oncology|2017Cited by 2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerMichael J. Overman, Thierry André, Sara Lonardi et al.|Journal of Clinical Oncology|2018Cited by 2.1k